OR WAIT null SECS
Sanofi and GlaxoSmithKline (GSK) have revealed that they are joining forces to develop an adjuvanted vaccine using their respective technologies that can be used to fight COVID-19.
Sanofi and GlaxoSmithKline (GSK) have revealed, in an April 14, 2020 press release, that they are joining forces to develop an adjuvanted vaccine using their respective technologies that can be used to fight COVID-19.
The technologies to be contributed by each company for the project include Sanofi’s S-protein COVID-19 antigen and GSK’s pandemic adjuvant technology. It is hoped that by combining a protein-based antigen with an adjuvant the companies will be able to develop an effective vaccine that can be manufactured at scale.
“As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus,” said Paul Hudson, CEO Sanofi, in the press release.
Emma Walmsley, CEO GSK, added, “This collaboration brings two of the world’s largest vaccines companies together. By combining our science and our technologies, we believe we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19.”